Copyright
©The Author(s) 2021.
World J Crit Care Med. Jan 9, 2021; 10(1): 22-34
Published online Jan 9, 2021. doi: 10.5492/wjccm.v10.i1.22
Published online Jan 9, 2021. doi: 10.5492/wjccm.v10.i1.22
Parameters | Survivor group | P value | |
Pre CytoSorb® therapy, mean ± SD | Post CytoSorb® therapy, mean ± SD | ||
Heart rate, beats/min | 118.57 ± 19.8 | 103.07 ± 19.38 | 0.00651 |
MAP, mmHg | 68.61 ± 9.62 | 79.42 ± 9.05 | 0.00011 |
GCS | 9.86 ± 2.34 | 12.20 ± 1.47 | 0.00011 |
PaCO2 | 43.32 ± 18.63 | 38.57 ± 11.66 | 0.2757 |
PaO2/FiO2 | 162.09 ± 82.99 | 161.20 ± 66.58 | 0.9704 |
- Citation: Paul R, Sathe P, Kumar RS, Prasad S, Aleem M, Sakhalvalkar P. Multicentered prospective investigator initiated study to evaluate the clinical outcomes with extracorporeal cytokine adsorption device (CytoSorb®) in patients with sepsis and septic shock. World J Crit Care Med 2021; 10(1): 22-34
- URL: https://www.wjgnet.com/2220-3141/full/v10/i1/22.htm
- DOI: https://dx.doi.org/10.5492/wjccm.v10.i1.22